TABLE 5.
Hemagglutination-inhibitory activity against Pan/99 virus of sera from guinea pigs immunized with Pan/99-based live attenuated vaccine
| Treatment and guinea pig | Vaccine | Route of challengec | Titer
|
||
|---|---|---|---|---|---|
| Preimmune | Postvaccinationd | Postchallengee | |||
| Live attenuated vaccine, homologous challengea | |||||
| 47 | PBS | Inoculation i.n. | 10 | 10 | 320 |
| 48 | PBS | Inoculation i.n. | 10 | 10 | 320 |
| 49 | PBS | Exposure | 10 | 10 | 320 |
| 50 | PBS | Exposure | 10 | 10 | 160 |
| 51 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 320 | 160 |
| 52 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 320 | 320 |
| 53 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 320 | 320 |
| 54 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 160 | 160 |
| 55 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 320 | 320 |
| 56 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 320 | 320 |
| 57 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 160 | 160 |
| 58 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 160 | 160 |
| Live attenuated vaccine, heterologous challengeb | |||||
| 59 | PBS | Inoculation i.n. | 10 | 10 | 20 |
| 60 | PBS | Inoculation i.n. | 10 | 10 | 20 |
| 61 | PBS | Exposure | 10 | 10 | 10 |
| 62 | PBS | Exposure | 10 | 10 | 80 |
| 63 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 1,280 | 1,280 |
| 64 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 1,280 | 2,560 |
| 65 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | <10 | 640 | 640 |
| 66 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 2,560 | 2,560 |
| 67 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 1,280 | 5,120 |
| 68 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 5,120 | 2,560 |
| 69 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 1,280 | 2,560 |
| 70 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 1,280 | 2,560 |